<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3292657/" ref="ordinalpos=4984&amp;ncbi_uid=4753575&amp;link_uid=PMC3292657" image-link="/pmc/articles/PMC3292657/figure/F4/" class="imagepopup">Figure 4. ERK1/2 <span class="highlight" style="background-color:">signaling</span> affects osteogenesis via regulating WNT/β-catenin <span class="highlight" style="background-color:">pathway</span>.  From: Basic Fibroblast Growth Factor Inhibits Osteogenic Differentiation of SHED through ERK <span class="highlight" style="background-color:">Signaling</span>. </a></div><br /><div class="p4l_captionBody"><b>(A)</b> Western blot analysis showed that bFGF reduced expression level of total β-catenin and active- β-catenin. β-actin was used as an internal control. Three independent assays showed similar results (*P&lt;0.05). <b>(B)</b> bFGF treatment decreased β-catenin expression level and ERK1/2 inhibitor treatment increased β-catenin levels. β-actin was used as an internal control. Three independent assays showed similar results (*P&lt;0.05). (<b>C</b>) bFGF activates ERK1/2 through RAS and MEK. Phosphorylated ERK1/2 inhibited β-catenin expression and then bone formation was reduced.</div></div>